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Abstract 
Introduction: The objective of the study was to evaluate changes in serum thyroid hormone levels in psychiatric patients after second-
-generation antipsychotic (SGA) treatment, and to determine differences between monotherapy and polytherapy with SGAs, as well as 
differences between patients with and without a history of antipsychotics.
Material and methods: A total of 71 patients with baseline thyroid hormone levels within the normal reference ranges were included in 
this retrospectively study.
Results: After SGAs treatment, the serum levels of free triiodothyronine (FT3), free thyroxine (FT4), total triiodothyronine (TT3), and total 
thyroxine (TT4) significantly decreased, and serum thyroid-stimulating hormone (TSH) levels significantly increased (changes from baseline: 
FT3: –0.31 pmol/L, p < 0.001; FT4: –2.71 pmol/L, p < 0.001; TT3: –0.05 nmol/L, p = 0.024, TT4: –12.36 nmol/L, p < 0.001; TSH: 0.46 mIU/L, 
p < 0.001). One (1.4%) patient had TSH levels higher than 7 mIU/L. Changes in serum levels of TSH and TT3 between patients with or 
without a history of antipsychotic drugs were significantly different (changes from baseline: TSH: p < 0.001 vs. p = 0.089; TT3: p = 0.013 
vs. p = 0.553). Changes in serum TSH levels had a moderate positive correlation with the average daily dose of SGAs (p = 0.007, r = 0.318).
Conclusions: After SGA treatment, patients seemed to have a trend of hypothyroidism, but the incidence was low. The preliminary results 
of this study did not show the necessity of regular monitoring of serum thyroid hormone levels in patients with baseline thyroid hormone 
levels within the normal reference ranges. (Endokrynol Pol 2020; 71 (4): 292–298)
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Introduction
Second-generation antipsychotics (SGAs), also known 
as atypical antipsychotics, are the most widely used 
antipsychotics. Some receptors can be blocked by SGAs, 
such as dopamine D1, D2, D3, D4 receptors, serotonin 
5-HT1A, 5-HT2A receptors, adrenergic a1, a2 receptors, 
histamine H1 receptors, and muscarinic M1 receptors 
[1]. Some SGAs can block all of these receptors, like 
clozapine, while most of them can only block some of 
these receptors [1], among which, dopamine D2 recep-
tors can be blocked by every SGA to varying extents [2]. 
Dopamine can inhibit the response of thyroid-stim-
ulating hormone (TSH) to thyrotropin-releasing 
hormone (TRH), and blocking dopamine receptors 
can cause a significant increase in serum TSH levels 
[3–5]. Second-generation antipsychotics, as dopamine 
D2 receptor antagonists, may elevate serum TSH levels, 
thereby affecting other thyroid hormone levels, such 
as triiodothyronine (T3) and thyroxine (T4). However, 
studies on changes in thyroid hormone levels in pa-
tients treated with SGAs are limited. Only a few studies 
focused on SGAs in monotherapy, and the results were 
inconsistent [6–8].
Conventionally, antipsychotic treatment is initiated 
with a single SGA, which is defined as monotherapy. 
When patients do not respond to monotherapy or the 
response is suboptimal, other SGAs will be added, or 
the former SGA will be switched to other SGAs, which 
can be defined as polytherapy. As far as we know, no 
previous study has reported the comparison of changes 
in thyroid hormone levels between SGA monotherapy 
versus polytherapy.
The first aim of this study was to evaluate changes 
in thyroid hormones in psychiatric patients after SGA 
treatment. Based on that, the second aim was to de-
termine differences between SGA monotherapy and 
polytherapy, and the third aim was to determine dif-
ferences between patients with or without a history of 
antipsychotics.
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Data were reported as number (percentage) for categorical 
variables, and median (first quartile = Q1, third quartile = Q3) 
for continuous variables. The comparison of demographic and 
clinical characteristics between subgroups was performed using 
Mann-Whitney U test for continuous variables, and chi-squared 
test or Fisher’s exact test for categorial variables, as appropriate. 
Wilcoxon matched-pairs rank test was used to compare thyroid 
hormone levels at baseline and after SGA treatment. Spearman’s 
rank correlation test was used to calculate correlations between 
serum thyroid hormone levels and the average daily dose of SGAs, 
as well as the duration of SGA treatment. All tests of hypothesis 
were two-tailed with a type-I error rate fixed at 5% (a = 0.05). All 
statistical analyses were performed using IBM SPSS 20.0 software 
(IBM SPSS, Inc., Chicago, IL, USA).
Results
Table 1 shows the demographic and clinical character-
istics of the subjects, as well as differences in subgroup 
analysis. A total of 71 subjects were enrolled in the 
study. A total of eight SGAs were prescribed in different 
treatment regimens, with a maximum of three SGAs 
per patient. The most frequently prescribed SGA was 
risperidone (36 subjects, 50.7%). More people in the 
polytherapy group were treated with clozapine and 
aripiprazole than in the monotherapy group (clozapine: 
40.7% vs. 4.5%, p < 0.001; aripiprazole: 33.3% vs. 4.5%, 
p = 0.004). A longer duration treatment of SGAs was 
observed in the polytherapy group compared with the 
monotherapy group (median 129 vs. 56 days, p < 0.001). 
In the other subgroup analysis, a significant difference 
was only found in age at psychiatric disorder onset, 
which was younger in the not-ADN group than in the 
ADN group (median 27 vs. 37 years, p < 0.001).
Changes in serum levels of FT3, FT4, TT3, TT4, and 
TSH from baseline after SGAs treatment are shown in 
Table 2. Also, comparisons between the monotherapy 
group and the polytherapy group, as well as the ADN 
group and the not-ADN group are outlined in this 
table. After SGA treatment, FT3 levels in one (1.4%) 
patient, FT4 levels in 11 (15.5%) patients, and TT4 lev-
els in three (4.2%) patients were all below the normal 
reference ranges. The TSH level in four (5.6%) patients 
were higher than the normal reference range. Among 
them, only one (1.4%) patient had TSH levels higher 
than 7 mIU/L. No subject developed hypothyroidism.
Spearman rank correlation test results showed 
a moderate positive correlation between changes in 
serum TSH levels and the average daily dose of SGAs 
(p = 0.007, r = 0.318). No correlation was found between 
changes in thyroid hormone levels and duration of SGA 
treatment (p > 0.05).
Material and methods
Patient population
The Ethics Committee of the Zhongshan Third People’s Hospital 
approved this study. Because this was a retrospective, non-
interventional study and all data were collected anonymously, 
informed consent was not required. The medical records of in-
patients at a psychiatric hospital, the Zhongshan Third People’s 
Hospital, from 1st November 2011 to 16th December 2019, were 
retrospectively reviewed.
Inclusion criteria were as follows: (i) patients aged 18 to 65 years; 
(ii) without treatment for psychosis or treatment that may affect 
thyroid function for at least six months prior; (iii) had received SGAs 
within 24 hours after admission, and continuously received SGA 
treatment; (iv) and had received SGAs treatment for at least 14 days. 
Exclusion criteria: (i) not all five baseline thyroid hormone levels, i.e. 
free T3 (FT3), free T4 (FT4), total T3 (TT3), total T4 (TT4), and TSH, 
were within the normal reference ranges; (ii) had taken medica-
tions known to affect thyroid hormones, such as antithyroid drugs 
(methimazole = thiamazole, carbimazole, and propylthiouracil), 
medicines contain iodine, levothyroxine, or lithium during the 
study period; (iii) pregnant or breastfeeding women. 
Variables
The following data from the medical records of each patient were 
collected: gender, age at admission, age at disease onset, smoking 
habit, weight, history of antipsychotic treatment, psychiatric diag-
nosis, SGA treatment (total dose and duration of use), concomitant 
medications, and serum thyroid hormone levels (including FT3, 
FT4, TT3, TT4, and TSH) at baseline and after admission within 
one year. The first test result of serum thyroid hormone levels with 
a minimum of 14 days of SGA treatment was taken as the serum 
thyroid hormone levels at follow-up. 
Serum thyroid hormone levels were measured by chemilumines-
cent enzyme immunoassay using the Access 2 Immunoassay System 
(Beckman Coulter, Inc., Fullerton, CA, USA). The normal reference 
ranges of serum thyroid hormone levels were as follows: FT3: 
3.28–6.47 pmol/L, FT4: 7.64–16.03 pmol/L, TT3: 1.01–2.48 nmol/L, 
TT4: 69.97–152.52 nmol/L, and TSH: 0.49–4.91 mIU/L. 
Diagnoses were made by psychiatrists according to the 10th revi-
sion of the International Classification of Diseases. During hos-
pitalisation, blood samples were drawn between 07:00 and 08:00 
before breakfast, for evaluation of serum thyroid hormone levels. 
According to the Defined Daily Dose (DDD) of the World Health 
Organisation, the dose of each SGA was converted into olanzapine 
equivalents [9]. The average daily dose of SGAs was calculated as 
the total dose divided by the total number of days of SGA treatment.
In the subgroup analysis between patients who received SGA 
monotherapy or polytherapy, the enrolled subjects were divided 
into two groups: the monotherapy group and the polytherapy 
group. Here, we referred to monotherapy as consistent use of one 
SGA, and polytherapy as a combination of more than one SGA, or 
switch from one SGA to another SGA, with each SGA taken for at 
least 14 days. Another subgroup analysis was performed between 
the antipsychotic drug-naïve group (ADN) containing patients with 
no history of antipsychotics, and the not-ADN group containing 
patients with a history of antipsychotics.
The concomitant medications were grouped into nine categories: 
anxiolytics, antidepressants, mood stabilisers, hypnotics, first-gener-
ation antipsychotics (FGAs), antiparkinsonian agents, antidementia 
agents, anticholinergics, and antiadrenergic agents. Information on 
the use of other medications that were unlikely to affect thyroid 
function, such as diuretics, laxatives, expectorants, nonsteroidal 
anti-inflammatories, and antibiotics, was not collected. Information 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this study, we analysed changes in serum thyroid 
hormone levels in psychiatric patients treated with 
SGAs. Also, we compared differences between SGA 
monotherapy and polytherapy, as well as differences 
between patients with or without a history of antipsy-
chotics. Our results showed a significant reduction in 
the serum levels of FT3, FT4, TT3, and TT4 and a sig-
nificant increase in serum TSH levels. These results 
indicate a possible trend of hypothyroidism after SGA 
treatment. However, only four (5.6%) patients devel-
oped subclinical hypothyroidism (the normal refer-
ence ranges < TSH < 10 mIU/L), without convincing 
symptoms suggestive of hypothyroidism. Only one 
(1.4%) of the four patients had TSH levels high enough 
(> 7 mIU/L) to need treatment for subclinical hypo-
thyroidism [10]. In other words, patients with normal 
baseline thyroid hormone levels had a low incidence 
of hypothyroidism after SGA treatment. 
Because SGA polytherapy may work when SGA 
monotherapy fails, changes in thyroid hormone lev-
els may also be different between the two treatment 
regimens. Surprisingly, subgroup analysis showed 
no significant difference in changes in serum thyroid 
hormone levels between SGA monotherapy and poly-
therapy. Another subgroup analysis found that serum 
levels of TSH and TT3 were probably more susceptible 
in patients who had ever taken antipsychotics before 
than in those who never had (changes from baseline: 
TSH p < 0.001 vs. p = 0.089; TT3 p = 0.013 vs. p = 0.553). 
Most of the existing studies in this area had been 
conducted among adolescents and children, with 
quetiapine being the most frequently studied. Two 
studies found a decrease in TT4 levels and an increase 
in TSH levels. One was an eight-week study includ-
ing 15 psychotic adolescents, which found trends for 
a decrease in TT4 levels and an increase in TSH levels 
after quetiapine treatment (p < 0.08) [11]. The other 
was a 12-week study involving 56 adolescents with 
schizophrenia, which found a significant decrease in 
TT4 levels (p < 0.001) and a significant increase in TSH 
levels (p = 0.014) after quetiapine treatment [12]. Two 
other studies had conflicting results. One was a multi-
centre, double-blind, randomised, placebo-controlled 
study in adolescents with bipolar depression, which 
found that extended-release (XR) quetiapine possibly 
elevated TSH levels compared to placebo (quetiapine 
XR: n = 92, 4.7%; placebo group: n = 100, 0%) but could 
not significantly change FT4 levels [13]. The other was 
a six-month follow-up study in psychotic children and 
adolescents, which found that FT4 decreased after 
quetiapine treatment (n = 24, changes from baseline 































































































































































































































































































































































































































































































































































































































































Antipsychotics and thyroid hormone Jia-Xuan Zhang, Xun Li
(n = 20, p > 0.05) or risperidone treatment (n = 22, 
p > 0.05), and TSH did not change significantly after 
any of the three antipsychotics [14]. The Canadian 
Alliance for Monitoring Effectiveness and Safety of 
Antipsychotics in Children guideline group recom-
mended scheduled repeat measurement of TSH levels 
in patients with normal TSH levels and assessment of 
FT4 in patients with abnormal TSH levels [15].
Studies in adults are limited, and the results are 
conflicting. A large cross-sectional study comparing pa-
tients with psychotic disorders (n = 1345 ) and healthy 
controls (n = 989 ) found that patients had lower FT4 
levels and higher TSH levels (FT4: 13.70 vs. 14.00 pmol/L, 
p < 0.001; TSH: 1.92 vs. 1.57 mIE/L, p < 0.001) [8]. Lower 
FT4 levels were associated with the use of antipsychot-
ics in general (n = 473, p = 0.001), and quetiapine 
(n = 66, p = 0.003), as well as olanzapine (n = 148, 
p = 0.018) in particular, but were not associated with 
the use of aripiprazole (n = 64, p = 0.402) or risperidone 
(n = 43, p = 0.472) [8]. Higher serum TSH levels were 
not associated with antipsychotics (p = 0.145) [8]. No 
correlations were found between total DDD of antipsy-
chotics and serum FT4 levels (p = 0.605), or serum TSH 
levels (p = 0.363) [8]. However, in our study, we found 
Table 2. Changes in serum of free triiodothyronine (FT3), free thyroxine (FT4), thyroid-stimulating hormone (TSH), 
total triiodothyronine (TT3), and total thyroxine (TT4) from baseline after second-generation antipsychotics treatment
Parameter N Baseline p Changes pc p
FT3 [pmol/L]
Total 71 5.08 (4.48, 5.39) –0.31 (–0.76, 0.21) < 0.001
Monotherapy 44 5.16 (4.53, 5.51)
0.594a
–0.29 (–0.80, 0.35) 0.027
0.474a
Polytherapy 27 5.05 (4.46, 5.39) –0.37 (–0.76, 0.08) 0.002
ADN 23 4.92 (4.44, 5.35)
0.403b
–0.46 (–0.95, 0.04) 0.004
0.173b
N-ADN 48 5.14 (4.53, 5.56) –0.25 (–0.74, 0.24) 0.021
FT4 [pmol/L]
Total 71 11.86 (10.54, 13.81) –2.71 (–3.67, –0.75) < 0.001
Monotherapy 44 11.87 (10.74, 13.86)
0.356a
–2.83 (–3.53, –1.02) < 0.001
0.683a
Polytherapy 27 11.64 (10.25, 13.73) –2.41 (–3.91, –0.60) < 0.001
ADN 23 11.84 (11.07, 13.87)
0.731b
–3.04 (–4.30, –1.02) < 0.001
0.212b
N-ADN 48 12.00 (10.35, 13.81) –2.66 (–3.35, –0.64) < 0.001
TSH [mIU/L]
Total 71 1.40 (0.89, 2.08) 0.46 (–0.06, 1.28) < 0.001
Monotherapy 44 1.35 (0.86, 2.03)
0.352a
0.44 (–0.03, 1.21) 0.001
0.943a
Polytherapy 27 1.44 (1.12, 2.10) 0.76 (–0.47, 1.59) 0.019
ADN 23 1.76 (0.92, 2.56)
0.253b
0.37 (–0.66, 1.99) 0.089
0.754b
N-ADN 48 1.29 (0.88, 1.99) 0.60 (–0.03, 1.23) < 0.001
TT3 [nmol/L]
Total 71 1.58 (1.37, 1.77) –0.05 (–0.30, 0.12) 0.024
Monotherapy 44 1.63 (1.38, 1.79)
0.431a
–0.05 (–0.23, 0.13) 0.163
0.410a
Polytherapy 27 1.54 (1.36, 1.74) –0.12 (–0.33, 0.12) 0.054
ADN 23 1.60 (1.37, 1.83)
0.849b
–0.01 (–0.47, 0.13) 0.553
0.410b
Not-ADN 48 1.58 (1.37, 1.77) –0.08 (–0.28, 0.06) 0.013
TT4 [nmol/L]
Total 71 123.52 (110.19, 135.47) –12.36 (–29.28, 3.13) < 0.001
Monotherapy 44 124.77 (110.92, 135.06)
0.953a
–11.43 (–30.01, 2.91) 0.004
0.758a
Polytherapy 27 122.31 (110.09, 137.32) –15.13 (–27.61, 7.67) 0.046
ADN 23 121.95 (110.05, 133.81)
0.685b
–20.87 (–29.74, 2.24) 0.009
0.892b
N-ADN 48 126.73 (112.95, 136.86) –10.63 (–28.86, 5.89) 0.011
N — number; ADN — antipsychotic drug naïve; N-ADN — not-antipsychotic drug naïve; adifference between the monotherapy group and the polytherapy group; 
bdifference between the antipsychotic drug-naïve and the not-antipsychotic drug-naïve; cdifference between baseline and after second-generation antipsychotic drug 
treatment
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a moderate positive correlation between changes in 
serum TSH levels and the average daily dose of SGAs 
(p = 0.007, r = 0.318). Another six-week study on treat-
ment-resistant schizophrenia patients found that TT4 
levels significantly decreased after quetiapine treatment 
(n = 10, –2.37 ± 1.48 µg/dL, t = 3.93, p = 0.01) but did 
not change after risperidone treatment (n = 11); TSH 
and FT4 did not change significantly after quetiapine 
or risperidone treatment [6]. As far as we know, only 
one study reported changes in the serum levels of 
FT3, FT4, TT3, TT4, and TSH in the same population, 
and its results were similar to ours. This was a study 
in depressed patients with bipolar disorder, which 
reported that FT3, FT4, and TT4 levels significantly 
decreased and TSH levels significantly increased after 
one-month quetiapine treatment, but TT3 did not 
change significantly (n = 58; FT4, TT4: p < 0.001; FT3: 
p = 0.011; TSH: p = 0.015; TT3: p = 0.425) [16]. After 
three-month quetiapine treatment, the serum levels of 
FT3, FT4, TT3, and TT4 significantly decreased, but TSH 
did not change significantly (n = 13) [16]. 
Two studies that focused on the risks of hypothy-
roidism both reported that quetiapine had a higher risk 
of hypothyroidism than other SGAs [17, 18]. One was 
a real-world study in patients with bipolar disorder, 
which found that the mean four-year risk of hypothy-
roidism in patients receiving lithium (n = 3629) was 
8.78%, and quetiapine (n = 3798) 8.26%, aripiprazole 
(n = 2964) 6.99%, risperidone (n = 1518) 6.46%, and 
olanzapine (n = 1230) 6.43% [17]. The other was a pro-
pensity score-adjusted cohort study, which reported 
a reduction of hypothyroidism in bipolar disorder 
patients taking olanzapine (n = 1477, hazard ratio [HR] 
0.48, p = 0.003), but not in patients taking quetiapine 
(n = 1376, HR 0.63, p = 0.074), compared to lithium 
(n = 2148) [18]. As confirmed by a previous study, 
lithium can induce hypothyroidism [19–21]. 
To the best of our knowledge, this is the first study 
that has compared differences of changes in thyroid 
hormone levels after treatment between SGAs poly-
therapy and monotherapy, as well as between patients 
with or without a history of antipsychotic drugs. In 
addition, we firstly reported no correlation between 
changes in thyroid hormone levels and the duration 
of SGAs treatment (p > 0.05). So far, of all the studies 
that have reported changes in thyroid hormone levels 
after SGAs treatment, this is the only study in which 
all five thyroid hormones of subjects were within the 
normal reference range at baseline.
Our study had some limitations. Due to the strict 
inclusion and exclusion criteria, the sample size was 
small. The eight SGAs were considered as a whole, but 
the pharmacological effects and usage frequency of 
each drug were not the same, thus changes in thyroid 
hormone levels after the monotherapy of each drug 
might be different. Concomitant medications may also 
affect thyroid hormones. However, most concomitant 
medications were not taken chronically. For example, 
first-generation antipsychotics were usually taken in 
the first week after admission. Therefore, the effects of 
concomitant medications on thyroid hormone levels 
may be limited. Another limitation was the lack of 
thyroid antibodies assessment and thyroid ultrasound 
examination, abnormal status of which could affect the 
results. In fact, patients would undergo thyroid antibod-
ies assessment or/and thyroid ultrasound examination 
when it was clinically indicated. Those diagnosed with 
thyroid abnormality, e.g. positive thyroid antibodies 
or thyroid nodules, would been excluded. Our results 
should be considered as a preliminary finding about 
changes in thyroid hormone levels after SGA treatment. 
Prospective studies with large sample sizes are needed 
to verify our finding.
Conclusion
After SGA treatment, psychiatric patients seemed to have 
a trend of hypothyroidism, but the incidence of hypothy-
roidism was low. The preliminary results of this study did 
not show the necessity of regular monitoring of serum 
thyroid hormone levels in patients with baseline thyroid 
hormone levels within the normal reference range.
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